Prediction of Low-Dose Aspirin-Induced Gastric Toxicity Using Nuclear Magnetic Resonance Spectroscopy-Based Pharmacometabolomics in Rats.
aspirin
gastric toxicity
multivariate analysis
nuclear magnetic resonance
pharmacometabolomic
spectroscopy
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
27
01
2022
revised:
21
03
2022
accepted:
22
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Low-dose aspirin (LDA) is the backbone for secondary prevention of coronary artery disease, although limited by gastric toxicity. This study aimed to identify novel metabolites that could predict LDA-induced gastric toxicity using pharmacometabolomics. Pre-dosed urine samples were collected from male Sprague-Dawley rats. The rats were treated with either LDA (10 mg/kg) or 1% methylcellulose (10 mL/kg) per oral for 28 days. The rats' stomachs were examined for gastric toxicity using a stereomicroscope. The urine samples were analyzed using a proton nuclear magnetic resonance spectroscopy. Metabolites were systematically identified by exploring established databases and multivariate analyses to determine the spectral pattern of metabolites related to LDA-induced gastric toxicity. Treatment with LDA resulted in gastric toxicity in 20/32 rats (62.5%). The orthogonal projections to latent structures discriminant analysis (OPLS-DA) model displayed a goodness-of-fit (R The study identified metabolic signatures that correlated with the development of a low-dose Aspirin-induced gastric toxicity in rats. This pharmacometabolomic approach could further be validated to predict LDA-induced gastric toxicity in patients with coronary artery disease.
Sections du résumé
BACKGROUND
BACKGROUND
Low-dose aspirin (LDA) is the backbone for secondary prevention of coronary artery disease, although limited by gastric toxicity. This study aimed to identify novel metabolites that could predict LDA-induced gastric toxicity using pharmacometabolomics.
METHODS
METHODS
Pre-dosed urine samples were collected from male Sprague-Dawley rats. The rats were treated with either LDA (10 mg/kg) or 1% methylcellulose (10 mL/kg) per oral for 28 days. The rats' stomachs were examined for gastric toxicity using a stereomicroscope. The urine samples were analyzed using a proton nuclear magnetic resonance spectroscopy. Metabolites were systematically identified by exploring established databases and multivariate analyses to determine the spectral pattern of metabolites related to LDA-induced gastric toxicity.
RESULTS
RESULTS
Treatment with LDA resulted in gastric toxicity in 20/32 rats (62.5%). The orthogonal projections to latent structures discriminant analysis (OPLS-DA) model displayed a goodness-of-fit (R
CONCLUSION
CONCLUSIONS
The study identified metabolic signatures that correlated with the development of a low-dose Aspirin-induced gastric toxicity in rats. This pharmacometabolomic approach could further be validated to predict LDA-induced gastric toxicity in patients with coronary artery disease.
Identifiants
pubmed: 35408523
pii: molecules27072126
doi: 10.3390/molecules27072126
pmc: PMC9000689
pii:
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
Nat Rev Gastroenterol Hepatol. 2011 Jun 07;8(7):385-94
pubmed: 21647198
Mol Biosyst. 2015 Jan;11(1):13-9
pubmed: 25382277
Prog Nucl Magn Reson Spectrosc. 2011 Oct;59(3):263-70
pubmed: 21920221
PLoS One. 2014 Sep 19;9(9):e107626
pubmed: 25238064
Nature. 2006 Apr 20;440(7087):1073-7
pubmed: 16625200
J Multidiscip Healthc. 2014 Mar 03;7:137-46
pubmed: 24741318
Nat Protoc. 2007;2(11):2692-703
pubmed: 18007604
J Biomed Inform. 2015 Feb;53:291-9
pubmed: 25499899
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
J Pharm Biomed Anal. 2016 Sep 10;129:492-501
pubmed: 27497650
Nature. 2011 Apr 7;472(7341):57-63
pubmed: 21475195
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
J Proteome Res. 2012 Apr 6;11(4):2427-40
pubmed: 22384821
Emerg (Tehran). 2015 Spring;3(2):48-9
pubmed: 26495380
J Am Coll Cardiol. 2015 Jul 7;66(1):74-85
pubmed: 26139061
J Proteome Res. 2013 Mar 1;12(3):1399-407
pubmed: 23336624
J Pharmacol Methods. 1985 Feb;13(1):59-66
pubmed: 3974255
J Proteome Res. 2012 Aug 3;11(8):4338-50
pubmed: 22800120
Biomol Ther (Seoul). 2016 Jan;24(1):1-8
pubmed: 26759695
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Anal Chim Acta. 2012 Apr 13;722:87-94
pubmed: 22444538
Clin Pharmacol Ther. 1993 Jul;54(1):84-9
pubmed: 8330469
Phytomedicine. 2016 Jun 1;23(6):662-71
pubmed: 27161407
Sci Rep. 2016 Aug 02;6:30693
pubmed: 27480133
Methods Mol Biol. 2007;358:247-71
pubmed: 17035690